Cytek Biosciences, Inc. (CTKB)
NASDAQ: CTKB · Real-Time Price · USD
5.15
-0.04 (-0.68%)
Jan 28, 2026, 11:06 AM EST - Market open
Cytek Biosciences Employees
Cytek Biosciences had 692 employees as of September 30, 2025. The number of employees increased by 47 or 7.29% compared to the same quarter last year.
Employees
692
Change
47
Growth
7.29%
Revenue / Employee
$284,434
Profits / Employee
-$18,526
Market Cap
657.86M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Sep 30, 2025 | 692 | 47 | 7.29% | 692 | 0 |
| Jun 30, 2025 | 688 | 43 | 6.67% | 688 | 0 |
| Mar 31, 2025 | 663 | 26 | 4.08% | 663 | 0 |
| Dec 31, 2024 | 648 | -28 | -4.14% | 648 | 0 |
| Sep 30, 2024 | 645 | -43 | -6.25% | 645 | 0 |
| Jun 30, 2024 | 645 | -54 | -7.73% | 645 | 0 |
| Mar 31, 2024 | 637 | -45 | -6.60% | 637 | 0 |
| Dec 31, 2023 | 676 | 93 | 15.95% | 676 | 0 |
| Sep 30, 2023 | 688 | 114 | 19.86% | 688 | 0 |
| Jun 30, 2023 | 699 | 144 | 25.95% | 699 | 0 |
| Mar 31, 2023 | 682 | 171 | 33.46% | 682 | 0 |
| Dec 31, 2022 | 583 | 81 | 16.14% | 583 | 0 |
| Sep 30, 2022 | 574 | 112 | 24.24% | 574 | 0 |
| Jun 30, 2022 | 555 | 126 | 29.37% | 555 | 0 |
| Mar 31, 2022 | 511 | 120 | 30.69% | 511 | 0 |
| Dec 31, 2021 | 502 | 111 | 28.39% | 496 | 6 |
| Sep 30, 2021 | 462 | 71 | 18.16% | 462 | 0 |
| Jun 30, 2021 | 429 | - | - | 429 | 0 |
| Mar 31, 2021 | 391 | - | - | 390 | 1 |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Varex Imaging | 2,400 |
| Avanos Medical | 2,227 |
| Orthofix Medical | 1,616 |
| Tactile Systems Technology | 1,037 |
| Bioventus | 950 |
| Standard BioTools | 818 |
| Pacific Biosciences of California | 575 |
| SI-BONE | 349 |
CTKB News
- 13 days ago - Cytek Biosciences, Inc. (CTKB) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript - Seeking Alpha
- 16 days ago - Cytek Biosciences Announces Preliminary Fourth Quarter and Full Year 2025 Revenue Results - GlobeNewsWire
- 2 months ago - Cytek Biosciences Is A Speculative Buy On Recurring Revenue Growth - Seeking Alpha
- 2 months ago - TIME Recognizes Cytek® Biosciences as One of America's Growth Leaders of 2026 - GlobeNewsWire
- 2 months ago - Cytek® Muse® Micro Cell Analyzer Wins BioTech Breakthrough Award for Drug Discovery Solution of the Year - GlobeNewsWire
- 2 months ago - Cytek Biosciences to Participate in Upcoming Investor Conferences - GlobeNewsWire
- 2 months ago - Cytek Biosciences, Inc. (CTKB) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 2 months ago - Cytek Biosciences Reports Third Quarter 2025 Financial Results - GlobeNewsWire